Discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside.
-
Research
-
Repurposing Drugs
OpenData Portal: Sharing Data to Advance COVID-19 Research
NCATS created a new resource for scientists, the OpenData Portal, to openly and quickly share COVID-19-related drug repurposing data and experiments for all approved drugs.
Late-Stage RepurposingPreparing therapeutic leads for clinical testing and evaluation.
Core TechnologiesUsing state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.
Preparing therapeutic leads for clinical testing and evaluation.
Using state-of-the-art resources to enable the ongoing operation of all NCATS translational research activities.
Collaboration and Funding Information
For collaboration and funding information related to drug repurposing, see:
Drug Repurposing at NCATS
Discoveries about the molecular basis of disease provide unprecedented opportunities to translate research findings into new medicines. However, developing a brand-new drug takes an enormous amount of time, money and effort, mainly due to bottlenecks in the therapeutic development process. Delays and barriers mean that translation of a promising molecule into an approved drug often takes more than 14 years. It is crucial to advance strategies to reduce this time frame, decrease costs and improve success rates.
Drug repurposing is one such strategy. Many agents approved for other uses already have been tested in humans, so detailed information is available on their pharmacology, formulation and potential toxicity. Because repurposing builds upon previous research and development efforts, new candidate therapies could be ready for clinical trials quickly, speeding their review by the Food and Drug Administration and, if approved, their integration into health care.
-
